Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

hcplive.com image

News from hcplive.com

See all of hcplive.com news coverage in one place. Discover how hcplive.com’s media bias informs their coverage and compare with thousands of other news outlets.

Ground News has come across 782 headlines reported on by hcplive.com during the past 3 months.

hcplive.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is hcplive.com credible or reliable? Our Factuality score answers both of those questions. When it comes to hcplive.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about hcplive.com

Where is hcplive.com located?hcplive.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top hcplive.com News

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Enanta Pharma (NASDAQ:ENTA), AbbVie (NYSE:ABBV)

Hepatitis C · United States

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Enanta Pharma (NASDAQ:ENTA), AbbVie (NYSE:ABBV)

73% Center coverage: 15 sources

Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV. The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc's (NYSE:ABBV) Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis or with compensated cirrhosis. Glecaprevir, one of the two DAAs in Mavyret, was…See the Story

The American Diabetes Association Debuts the 85th Scientific Sessions with Breakthrough Diabetes Research

Diabetes · United States

The American Diabetes Association Debuts the 85th Scientific Sessions with Breakthrough Diabetes Research

86% Center coverage: 7 sources

/PRNewswire/ -- From June 20–23, the American Diabetes Association® (ADA) will host the 85th Scientific Sessions in Chicago. The ADA's Scientific Sessions is...See the Story

How You Can Help Protect Your Baby Against Rotavirus

Hospitals · United States

How You Can Help Protect Your Baby Against Rotavirus

67% Center coverage: 3 sources

(BPT) - If you are a parent, you may have heard about rotavirus — an easily spread disease that can pose a serious risk to infants and young children. Symptoms can include mild to severe diarrhea, vomiting and fever. In ...See the Story

FDA Approves Prednisolone Acetate Ophthalmic Suspension for Ocular Inflammation

100% Center coverage: 1 sources

The FDA has approved preodnisolone acetate ophthalmic suspension, USP 1%, for treating steroid-responsive ocular inflammation. Amneal Pharmaceuticals plans to launch the product in Q3...FDA · United States See the Story

Sickle Cell Patients to Get Better Treatment After £9m Boost (UK Department of Health & Social Care)

100% Center coverage: 1 sources

) Patients with sickle cell disease are set to benefit from quicker and more accessible treatment thanks to major upgrades to life saving technology. Backed by a £9million investment from NHS England, the government is set to transform apheresis services - a specialised set of treatments which remove harmful components from a patient's blood - by funding more specialist treatment centres, as well as expanding access to cutting-edge technology. F…United Kingdom · United Kingdom See the Story

Biologics and Beyond: Clinical Perspectives on Managing Complex Airway Inflammation

Explore the latest advancements in biologic therapies for asthma and COPD discussed in a recent clinical forum highlighting personalized medicine and biomarker-driven strategies for improved patient outcomes.Read Article

Classifying Obesity as a Chronic Disease with W. Timothy Garvey, MD

The recent Lancet Commission on Obesity has repositioned the former risk factor as a disease, indicating and emphasizing a variety of complications.Maryland · Maryland Read Article

Successful HCV Treatment with DAAs Linked to Lower Extrahepatic Manifestation Risk

Successful HCV treatment with DAAs was associated with reduced risks of CKD, stroke, major adverse cardiac events, and neurocognitive disorders.Read Article

Dual Agonists and Upstream Obesity Treatment with Kausik Ray, FMedSci

By targeting insulin resistance at its source, dual receptor agonists may have a more efficient method of tackling the growing obesity problem, as well as its cardiovascular effects.Read Article

Inebilizumab Efficacy and Safety Consistent Across Demographic Subgroups of IgG4-RD

Inebilizumab was approved by the FDA under the name Uplizna as the first and only treatment for adult patients with IgG4-RD in April 2025FDA · United States Read Article

Efficacy, Safety of Deucravacitinib for Psoriasis, with Milaan Shah, MD

In this interview with Milaan Shah, MD, the expert consensus panel reviewing deucravacitinib’s safety and efficacy for psoriasis is discussed.Maryland · Maryland Read Article

Breaking News Topics Related to hcplive.com